Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.
/ 3 items
#HRMY↓
Harmony Biosciences Faces Patent Setback: Analyst Downgrades Stock
Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.
Harmony Biosciences Drug Fails Fragile X Trial: What Went Wrong?
Harmony Biosciences’ experimental drug ZYN002 failed its Phase 3 trial for Fragile X syndrome, failing to meet its main goal for improving social avoidance primarily due to a high placebo response.